I-124 PET Directed Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer: the I-FIRST Study: Difference between revisions

From STARDIT
Jump to navigation Jump to search
VisualWikitext
wikispore>Pkdilena
(Created page with "{{item |type_parameter=research |description_parameter=For patients with advanced thyroid cancer, tumours that no longer trap radioiodine have an extremely poor prognosis and more effective treatments are urgently required. This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life. |aim_parameter={{aim parameter|This study will examine whether redifferentiation therap...")
 
m (3 revisions imported: Import Stardit pages from Wikispore.)
 
(2 intermediate revisions by 2 users not shown)
Line 2: Line 2:
|type_parameter=research
|type_parameter=research
|description_parameter=For patients with advanced thyroid cancer, tumours that no longer trap radioiodine have an extremely poor prognosis and more effective treatments are urgently required. This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life.
|description_parameter=For patients with advanced thyroid cancer, tumours that no longer trap radioiodine have an extremely poor prognosis and more effective treatments are urgently required. This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life.
|aim_parameter={{aim parameter|This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life}}{{aim parameter|. We will also determine the affordability of bringing this therapy to the clinic}}
|aim_parameter={{aim parameter|This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life}}{{aim parameter|We will also determine the affordability of bringing this therapy to the clinic}}
|state_parameter=ongoing
|state_parameter=ongoing
|start_date_parameter=2021-01-01
|start_date_parameter=2021-01-01
Line 8: Line 8:
|location_parameter=Australia
|location_parameter=Australia
|location_link=No
|location_link=No
|URL_parameter=https://www.grants.gov.au/Ga/Show/6c463857-6f42-4bb8-ad2f-3933a356e2b0
|author_parameter={{author parameter
|aut_nam=Portia Dilena
|aut_url=https://scholars.latrobe.edu.au/pdilena
|aut_con=non contact
}}{{author parameter
|aut_nam=Jack Nunn
|aut_ids=0000-0003-0316-3254
|aut_url=https://orcid.org/0000-0003-0316-3254
|aut_tas=Checked report and added URL
|aut_con=non contact
}}
|contributor_parameter={{contributor parameter
|contributor_parameter={{contributor parameter
|con_typ=individual
|con_typ=individual
Line 13: Line 25:
|con_tas=Lead Chief Investigator
|con_tas=Lead Chief Investigator
|con_url=https://www.onjcri.org.au/about-us/andrew-scott/
|con_url=https://www.onjcri.org.au/about-us/andrew-scott/
|con_cop=volunteer
|con_cop=paid
|con_dates=No
|con_dates=No
}}
}}
Line 19: Line 31:
|inp_typ=funding
|inp_typ=funding
|inp_inp=2,708,660.70
|inp_inp=2,708,660.70
|inp_currency=AUD
|inp_url=https://www.grants.gov.au/Ga/Show/6c463857-6f42-4bb8-ad2f-3933a356e2b0
}}
}}
}}
}}

Latest revision as of 21:22, 18 November 2023

Description: For patients with advanced thyroid cancer, tumours that no longer trap radioiodine have an extremely poor prognosis and more effective treatments are urgently required. This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life.
Dates

State ongoing
Start 2021-01-01
End 2026-01-01
Form updated 2023-11-18

Report authors
Portia Dilena (link)
Jack Nunn (link)
0000-0003-0316-3254
Checked report and added URL
Aims
This study will examine whether redifferentiation therapy is able to resensitize tumours to radioiodine treatment and improve patient survival and quality of life
We will also determine the affordability of bringing this therapy to the clinic
Category
research

Inputs

individual

Andrew Scott (link)


Task: Lead Chief Investigator
Compensation: paid
funding

(link)


2,708,660.70 (AUD)

Outputs and impacts

Retrieved from "https://stardit.wikimedia.org.au/w/index.php?title=I-124_PET_Directed_Redifferentiation_Therapy_for_Radioiodine_Refractory_Thyroid_Cancer:_the_I-FIRST_Study&oldid=322"